Pharma, Biotech, VCs Must Unite to Get Drugs to Market
Senior Staff Writer
PHILADELPHIA – With lengthy development cycles and the increasing costs of clinical work, well-established therapeutics sitting on pharmaceutical company shelves may be the lowest hanging fruit.
The question is: Who is going to pay for them? Big pharmas are challenged to bring all of the promising products to market, despite budget constraints; biotechs are challenged to find funding for their own technologies; and venture capital firms are challenged to get returns on investments.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-855-260-5607
Outside the U.S.: 1-646-822-4549
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter